Department of Radiation Oncology
Prostate Cancer
-
Technical Advantages
-
Equipment Advantages
-
Leading Experts
-
Treatment Cases
Technical Advantages
Technical Advantages
The Department of Radiation Oncology specializes in the precise diagnosis and treatment of prostate cancer. The technical advantages are as follows
-
Each patient receives a standardized and professional treatment plan developed through a multidisciplinary team (MDT) approach, based on evidence-based medicine; -
Precision radiotherapy techniques, including IMRT, IGRT, VMAT, and respiratory gating, and based on specific molecular targeted probe examinations (e.g., PSMA PET-CT), enable more precise irradiation, thereby improving tumor treatment outcomes while effectively reducing side effects; -
Access to the most advanced proton and heavy ion therapy resources and international consultation services, providing patients in need with the most advanced and authoritative treatment recommendations and related referral pathways currently available worldwide.
Equipment Advantages
Equipment Advantages
-
1
The latest generation GE Discovery MI PET/CT and NM/CT 870 SPECT/CT systems: Achieve comprehensive coverage from molecular imaging diagnosis of genitourinary tumors to routine split renal function (GFR) assessment. In particular, the application of the novel molecular probe 18F-PSMA (prostate-specific membrane antigen ligand) provides new tools for the early diagnosis, initial staging, biochemical recurrence and treatment response evaluation of prostate cancer, as well as the assessment of tumor heterogeneity and biological behavior.
-
2
The world's most advanced Hitachi proton and heavy ion integrated radiotherapy system: Utilizes internationally leading proton and heavy ion technologies. Proton and heavy ion therapy features a unique "Bragg peak" effect, enabling precise delivery of radiation energy to the tumor tissue while significantly minimizing damage to normal tissues. This is particularly beneficial for pediatric tumors, head and neck cancers, brain tumors, hepatobiliary and pancreatic tumors, and patients with poor tolerance to radiotherapy.
-
3
Varian TrueBEAM with HyperArc: The Varian TrueBEAM linear accelerator equipped with HyperArc technology enables ultra-high precision stereotactic body radiotherapy (SBRT/SRS). HyperArc technology can precisely treat multiple tumor lesions in a single session within a very short time, especially suitable for patients with brain metastases, significantly improving tumor control rates, reducing the number of treatment sessions, and enhancing the patient treatment experience.
-
4
Adaptive Radiotherapy (Adaptive RT): Employs cutting-edge adaptive radiotherapy technology, allowing real-time adjustment of the treatment plan based on changes in tumor morphology and position throughout the radiotherapy course. Through real-time image monitoring and precise dynamic adjustments, it effectively enhances treatment efficacy, maximizes the protection of normal tissues, and ensures that each patient receives the most precise and safest treatment experience.
Leading Experts
National High-Level Talent, National Distinguished Expert, Chief Scientist of the National Key R&D Program; Professor at Soochow University, Clinical Oncology Professor at Fudan University; Former Executive Vice President of Shanghai Proton and Heavy Ion Hospital, Former Vice President of Singapore General Hospital; Member of the Steering Committee of Heyou International Hospital Group, Vice President of Heyou Hospital; Director of the Oncology Medical Center and Proton and Heavy Ion Center, Heyou Hospital.
Clinical Cases
-
HeYou Hospital Multidisciplinary Collaboration Helps 57-Year-Old Hong Kong Patient Achieve Tumor-Free Survival from Prostate Cancer
-
Patient Profile
60-Year-Old Male
-
Chief Complaints
Elevated PSA (Prostate-Specific Antigen) level detected during a routine health check-up, with subsequent continuous rise over the following months
-
Treatment Process
A multidisciplinary team led by Professor Xie Keji and Professor Lu Jiade, comprising specialists from Urology, Radiation Oncology, Medical Oncology, Radiology, and Pathology, conducted a detailed analysis of Mr. Wu's condition. Experts from Urology, Radiation Oncology, and Medical Oncology, considering the patient's disease characteristics and based on domestic and international treatment guidelines and advancements, proposed two treatment options: "surgery" and "precision radiotherapy combined with endocrine therapy." They thoroughly communicated the efficacy, side effects, and treatment schedules of both options with the patient. After being fully informed and giving careful consideration, Mr. Wu decided to proceed with the comprehensive treatment plan of "precision radiotherapy combined with endocrine therapy." Subsequently, in the Department of Radiation Oncology, Mr. Wu successfully completed 39 sessions of precision radiotherapy. HeYou Hospital utilized Image-Guided Radiotherapy (IGRT) and Intensity-Modulated Radiotherapy (IMRT) techniques, combined with meticulous bladder and bowel preparation before each session, to ensure precise irradiation of cancer cells while minimizing damage to normal tissues to the lowest level. Concurrently, endocrine therapy was initiated simultaneously.
-
Therapeutic Outcomes
In January 2025, PSA levels returned to normal, indicating effective tumor control
-
